Long-term data: No difference in cardiovascular mortality or morbidity with transdermal estradiol vs. LHRH agonists for androgen suppression in prostate cancer
15 Feb, 2021 | 00:31h | UTCTransdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme – The Lancet (link to abstract – $ for full-text)